Questions for Investor Call, page-68

This is a long one.


In 2013 the OBJ BOD announced that 'GSK had entered into a Phase II Analgesic Agreement with OBJ following the successful completion of a Phase I program conducted during 2012'; and in 2014 the OBJ BOD announced OBJ were 'Now awaiting clinical validation of optimised formulation.'; and in the 2015 Annual Report the OBJ BOD announced that GSK 'had re-engaged with OBJ following migration of it's medicated skincare R&D from New Jersey to the UK.  Excellent working relationships remain in place across GSK' & 'The international Joint venture, recently signed between GSK & Novartis potentially expands opportunities for the Company's technologies in the analgesic field with the new product development responsibilities and priorities under the JV expected to become clearer in the next quarter' & 'The Company currently has three programs with a number of GSK International brand groups covering oral healthcare, analgesics and medicated skincare'; and in 2016 GSK received only a one line mention for the whole year being 'and testing with GSK'; and in 2017 there has been absolutely no mention of GSK whatsoever - Can the OBJ BOD please provide a detailed update on the status of all GSK JV operations and update Shareholders as to the JV status of all ongoing GSK International brand groups?